Biogen is declaring success with a once-failed treatment for Alzheimer’s disease, pointing to positive secondary results from a mid-stage study in hopes of saving a drug many in the field had written off entirely.

The treatment, BAN2401, failed its primary goal of beating out placebo over the course of 12 months. But looking at 18 months worth of data from the Phase 2 trial, Biogen and its partner, Japanese drug maker Eisai, said late Thursday that one dose of the treatment — the highest of five tested — had a significant effect on both cognition and the accumulation of toxic plaques in the brain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi,
    Please tell me how I could be part of the BAN 2401 Study or receive this medication. I have early Alzheimers & take care of my special needs daughter. I am an otherwise healthy 76 year old man who makes people laugh. Thank you very much, Anthony Robbins

  • Terrific work Biogen. Great news that this result showed slowing of decreased cognitive ability.
    The next step is to get the drug to correlate to increased cognitive ability. It will happen!

  • Anavex Life Science (AVXL) drug has a totally different mechanism than these other failed drugs and has shown very promising phase 2 data. Phase 2b/3 trial starting within the next month or two.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy